



Model List of Essential Medicines



Daclatasvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 30 mg (as dihydrochloride); 60 mg (as dihydrochloride)

Indications

[Chronic hepatitis C](#)



Daclatasvir + sofosbuvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg

Indications

[Chronic hepatitis C](#)



Dasabuvir [General information](#)

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 250 mg tablet

Indications

[Chronic hepatitis C](#)



Elbasvir + grazoprevir [General information](#)

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 50 mg + 100 mg

Indications

[Chronic hepatitis C](#)



Glecaprevir + pibrentasvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid: 50 mg + 20 mg granules
- Oral > Solid > tablet: 100 mg + 40 mg

Indications

[Chronic hepatitis C](#)



Ledipasvir + sofosbuvir [General information](#)

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 90 mg + 400 mg tablet

Indications

[Chronic hepatitis C](#)



Ombitasvir + paritaprevir + ritonavir [General information](#)

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet

Indications

[Chronic hepatitis C](#)



Pegylated interferon alfa (2a) [General information](#)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

Indications

[Chronic hepatitis C](#)



Pegylated interferon alfa (2b) [General information](#)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

Indications

[Chronic hepatitis C](#)



Ravidasvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg

Indications

[Chronic hepatitis C](#)



Ribavirin [General information](#)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
- Oral > Solid: 200 mg; 400 mg; 600 mg

Indications

[Chronic hepatitis C](#)



Simeprevir [General information](#)

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

- Oral > Solid: 150 mg

Indications

[Chronic hepatitis C](#)



Sofosbuvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg; 400 mg
- Oral > Solid > granules: 200 mg in sachet

Indications

[Chronic hepatitis C](#)



Sofosbuvir + velpatasvir [General information](#)

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

- Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg
- Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet

Indications

[Chronic hepatitis C](#)